<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02857868</url>
  </required_header>
  <id_info>
    <org_study_id>CABL001A2103</org_study_id>
    <nct_id>NCT02857868</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects</brief_title>
  <official_title>A Phase I, Open-label, Multi-center, Single-dose Study to Evaluate the Pharmacokinetics of ABL001 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the effect of varying degrees of impaired
      hepatic function (by Child-Pugh classification) on the pharmacokinetics (PK) of ABL001 after
      a single oral dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2016</start_date>
  <completion_date type="Actual">June 23, 2017</completion_date>
  <primary_completion_date type="Actual">June 23, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Pharmacokinetics (PK): Cmax</measure>
    <time_frame>at pre- dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose</time_frame>
    <description>To evaluate the pharmacokinetics of a single oral dose of ABL001 in subjects with various degrees of impaired hepatic function (by Child-Pugh classification) relative to healthy subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Pharmacokinetics (PK): AUClast</measure>
    <time_frame>at pre- dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose</time_frame>
    <description>To evaluate the pharmacokinetics of a single oral dose of ABL001 in subjects with various degrees of impaired hepatic function (by Child-Pugh classification) relative to healthy subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Pharmacokinetics (PK): AUCinf</measure>
    <time_frame>at pre- dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose</time_frame>
    <description>To evaluate the pharmacokinetics of a single oral dose of ABL001 in subjects with various degrees of impaired hepatic function (by Child-Pugh classification) relative to healthy subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Secondary Pharmacokinetics (PK): Tmax</measure>
    <time_frame>at pre- dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose</time_frame>
    <description>To evaluate the pharmacokinetics of a single oral dose of ABL001 in subjects with various degrees of impaired hepatic function (by Child-Pugh classification) relative to healthy subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Secondary Pharmacokinetics (PK): T 1/2</measure>
    <time_frame>at pre- dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose</time_frame>
    <description>To evaluate the pharmacokinetics of a single oral dose of ABL001 in subjects with various degrees of impaired hepatic function (by Child-Pugh classification) relative to healthy subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Secondary Pharmacokinetics (PK): CL/F</measure>
    <time_frame>at pre- dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose</time_frame>
    <description>To evaluate the pharmacokinetics of a single oral dose of ABL001 in subjects with various degrees of impaired hepatic function (by Child-Pugh classification) relative to healthy subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Secondary Pharmacokinetics (PK): Vz/F</measure>
    <time_frame>at pre- dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose</time_frame>
    <description>To evaluate the pharmacokinetics of a single oral dose of ABL001 in subjects with various degrees of impaired hepatic function (by Child-Pugh classification) relative to healthy subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of plasma protein binding as expressed by unbound fraction in plasma</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>To evaluate ABL001 plasma protein binding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABL001 pharmacokinetic parameter - Cmax - based on unbound fraction in plasma</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>Unbound fraction I plasma includes but is not limited to unbound Cmax (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABL001 pharmacokinetic parameter - AUClast - based on unbound fraction in plasma</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>Unbound fraction I plasma includes but is not limited to unbound AUClast (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABL001 pharmacokinetic parameter - AUCinf - based on unbound fraction in plasma</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>Unbound fraction I plasma includes but is not limited to unbound AUCinf (AUCinf)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>ABL001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABL001</intervention_name>
    <arm_group_label>ABL001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion criteria:

          -  Body mass index of 18-36 kg/m2, with body weight 50 kg and no more than 120 kg

          -  Vital signs (after at least 3 minutes rest in the supine position) within the
             following ranges (inclusive):

               -  Oral body temperature between 35.0 °C - 37.5 °C (95.0-99.5°F)

               -  Systolic BP ≥90 mmHg and ≤140 mmHg

               -  Diastolic BP ≥60 mmHg and ≤90 mmHg for healthy subjects and 50-100 mmHg for
                  subjects with impaired hepatic function (groups 2-4)

               -  Pulse Rate: ≥50 and ≤90 bpm for healthy subjects (group 1) and ≥50 and ≤100 bpm
                  for subjects with impaired hepatic function (groups 2-4)

          -  Healthy subjects with no clinically significant abnormalities as determined by past
             medical history, physical examination, vital signs, ECG, and clinical laboratory test

          -  Subjects with Child-Pugh Clinical Assessment Score as calculated per the Child-Pugh
             classification

        Key Exclusion Criteria:

          -  Presence of clinically significant ECG abnormalities or a family history or presence
             of prolonged QT-interval syndrome

          -  History of cardiac disease

          -  Sexually active males must use a condom during intercourse while taking the drug and
             for 7 days after stopping

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism or excretion of drugs

          -  Administration of strong or moderate CYP3A4 inhibitors or inducers (including St
             John's wort) within 14 days prior to dosing

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami / Clinical Research Services, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Impairment</keyword>
  <keyword>ABL001</keyword>
  <keyword>Child-Pugh</keyword>
  <keyword>healthy subjects with normal hepatic function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

